Definium Therapeutics 焦虑症药物晚期试验达标,盘前股价飙升 22%

美股速递
Aug 12

Definium Therapeutics 的股价在盘前交易时段猛涨22%,原因在于该公司针对焦虑症的一款药物成功达成了后期临床试验的核心目标。这一喜讯瞬间点燃了市场热情,投资者纷纷涌入,推动股价大幅上扬。此次试验结果无疑为这家生物技术公司注入了强劲的发展动力,也为其在精神健康领域的布局增添了关键砝码。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10